Recall of disclosed apolipoprotein E genotype and lifetime risk estimate for Alzheimer's disease

The REVEAL study

Susan LaRusse Eckert, Heather Katzen, J. Scott Roberts, Melissa Barber, Lisa D. Ravdin, Norman R. Relkin, Peter J. Whitehouse, Robert C. Green

Research output: Contribution to journalArticle

26 Citations (Scopus)

Abstract

PURPOSE: To determine whether individuals recall their apolipoprotein E genotype and numeric lifetime risk estimates after undergoing a risk assessment for Alzheimer's disease. METHODS: One-hundred and four participants underwent Alzheimer's disease risk assessment that included disclosure of apolipoprotein E genotype and a numeric lifetime risk estimate. RESULTS: At six weeks and one year post-disclosure, 59% and 48% of participants, respectively, recalled their lifetime risk estimate, and 69% and 63% recalled their apolipoprotein E genotype. Participants were more likely to remember their genotype than numeric lifetime risk estimate at one year (P < 0.05). Apolipoprotein E epsi;4-positive participants had better recall of their genotype at both time points (P < 0.05). Participants were more likely to recall whether they carried the "risk-enhancing form of apolipoprotein E" than their specific genotype (P < 0.05). CONCLUSIONS: These data suggest that apolipoprotein E genotype, especially the presence of an &epsiv;4 allele, is more memorable than a numeric risk estimate for Alzheimer's disease. Participants recalled genotype information in a more simplified, binary form. Health professionals testing for complex disorders such as Alzheimer's disease must find an appropriate balance between communicating risk in an understandable format and addressing the probabilistic nature of the information.

Original languageEnglish
Pages (from-to)746-751
Number of pages6
JournalGenetics in Medicine
Volume8
Issue number12
DOIs
StatePublished - Dec 1 2006

Fingerprint

Apolipoproteins E
Alzheimer Disease
Genotype
Disclosure
Alleles
Health

Keywords

  • Alzheimer's disease
  • APOE
  • Genetic counseling
  • Genetic susceptibility testing
  • REVEAL
  • Risk information recall

ASJC Scopus subject areas

  • Genetics(clinical)
  • Genetics

Cite this

Eckert, S. L., Katzen, H., Roberts, J. S., Barber, M., Ravdin, L. D., Relkin, N. R., ... Green, R. C. (2006). Recall of disclosed apolipoprotein E genotype and lifetime risk estimate for Alzheimer's disease: The REVEAL study. Genetics in Medicine, 8(12), 746-751. https://doi.org/10.1097/01.gim.0000250197.44245.a3

Recall of disclosed apolipoprotein E genotype and lifetime risk estimate for Alzheimer's disease : The REVEAL study. / Eckert, Susan LaRusse; Katzen, Heather; Roberts, J. Scott; Barber, Melissa; Ravdin, Lisa D.; Relkin, Norman R.; Whitehouse, Peter J.; Green, Robert C.

In: Genetics in Medicine, Vol. 8, No. 12, 01.12.2006, p. 746-751.

Research output: Contribution to journalArticle

Eckert, SL, Katzen, H, Roberts, JS, Barber, M, Ravdin, LD, Relkin, NR, Whitehouse, PJ & Green, RC 2006, 'Recall of disclosed apolipoprotein E genotype and lifetime risk estimate for Alzheimer's disease: The REVEAL study', Genetics in Medicine, vol. 8, no. 12, pp. 746-751. https://doi.org/10.1097/01.gim.0000250197.44245.a3
Eckert, Susan LaRusse ; Katzen, Heather ; Roberts, J. Scott ; Barber, Melissa ; Ravdin, Lisa D. ; Relkin, Norman R. ; Whitehouse, Peter J. ; Green, Robert C. / Recall of disclosed apolipoprotein E genotype and lifetime risk estimate for Alzheimer's disease : The REVEAL study. In: Genetics in Medicine. 2006 ; Vol. 8, No. 12. pp. 746-751.
@article{99936418d05a4b7bac866f621777aa52,
title = "Recall of disclosed apolipoprotein E genotype and lifetime risk estimate for Alzheimer's disease: The REVEAL study",
abstract = "PURPOSE: To determine whether individuals recall their apolipoprotein E genotype and numeric lifetime risk estimates after undergoing a risk assessment for Alzheimer's disease. METHODS: One-hundred and four participants underwent Alzheimer's disease risk assessment that included disclosure of apolipoprotein E genotype and a numeric lifetime risk estimate. RESULTS: At six weeks and one year post-disclosure, 59{\%} and 48{\%} of participants, respectively, recalled their lifetime risk estimate, and 69{\%} and 63{\%} recalled their apolipoprotein E genotype. Participants were more likely to remember their genotype than numeric lifetime risk estimate at one year (P < 0.05). Apolipoprotein E epsi;4-positive participants had better recall of their genotype at both time points (P < 0.05). Participants were more likely to recall whether they carried the {"}risk-enhancing form of apolipoprotein E{"} than their specific genotype (P < 0.05). CONCLUSIONS: These data suggest that apolipoprotein E genotype, especially the presence of an &epsiv;4 allele, is more memorable than a numeric risk estimate for Alzheimer's disease. Participants recalled genotype information in a more simplified, binary form. Health professionals testing for complex disorders such as Alzheimer's disease must find an appropriate balance between communicating risk in an understandable format and addressing the probabilistic nature of the information.",
keywords = "Alzheimer's disease, APOE, Genetic counseling, Genetic susceptibility testing, REVEAL, Risk information recall",
author = "Eckert, {Susan LaRusse} and Heather Katzen and Roberts, {J. Scott} and Melissa Barber and Ravdin, {Lisa D.} and Relkin, {Norman R.} and Whitehouse, {Peter J.} and Green, {Robert C.}",
year = "2006",
month = "12",
day = "1",
doi = "10.1097/01.gim.0000250197.44245.a3",
language = "English",
volume = "8",
pages = "746--751",
journal = "Genetics in Medicine",
issn = "1098-3600",
publisher = "Lippincott Williams and Wilkins",
number = "12",

}

TY - JOUR

T1 - Recall of disclosed apolipoprotein E genotype and lifetime risk estimate for Alzheimer's disease

T2 - The REVEAL study

AU - Eckert, Susan LaRusse

AU - Katzen, Heather

AU - Roberts, J. Scott

AU - Barber, Melissa

AU - Ravdin, Lisa D.

AU - Relkin, Norman R.

AU - Whitehouse, Peter J.

AU - Green, Robert C.

PY - 2006/12/1

Y1 - 2006/12/1

N2 - PURPOSE: To determine whether individuals recall their apolipoprotein E genotype and numeric lifetime risk estimates after undergoing a risk assessment for Alzheimer's disease. METHODS: One-hundred and four participants underwent Alzheimer's disease risk assessment that included disclosure of apolipoprotein E genotype and a numeric lifetime risk estimate. RESULTS: At six weeks and one year post-disclosure, 59% and 48% of participants, respectively, recalled their lifetime risk estimate, and 69% and 63% recalled their apolipoprotein E genotype. Participants were more likely to remember their genotype than numeric lifetime risk estimate at one year (P < 0.05). Apolipoprotein E epsi;4-positive participants had better recall of their genotype at both time points (P < 0.05). Participants were more likely to recall whether they carried the "risk-enhancing form of apolipoprotein E" than their specific genotype (P < 0.05). CONCLUSIONS: These data suggest that apolipoprotein E genotype, especially the presence of an &epsiv;4 allele, is more memorable than a numeric risk estimate for Alzheimer's disease. Participants recalled genotype information in a more simplified, binary form. Health professionals testing for complex disorders such as Alzheimer's disease must find an appropriate balance between communicating risk in an understandable format and addressing the probabilistic nature of the information.

AB - PURPOSE: To determine whether individuals recall their apolipoprotein E genotype and numeric lifetime risk estimates after undergoing a risk assessment for Alzheimer's disease. METHODS: One-hundred and four participants underwent Alzheimer's disease risk assessment that included disclosure of apolipoprotein E genotype and a numeric lifetime risk estimate. RESULTS: At six weeks and one year post-disclosure, 59% and 48% of participants, respectively, recalled their lifetime risk estimate, and 69% and 63% recalled their apolipoprotein E genotype. Participants were more likely to remember their genotype than numeric lifetime risk estimate at one year (P < 0.05). Apolipoprotein E epsi;4-positive participants had better recall of their genotype at both time points (P < 0.05). Participants were more likely to recall whether they carried the "risk-enhancing form of apolipoprotein E" than their specific genotype (P < 0.05). CONCLUSIONS: These data suggest that apolipoprotein E genotype, especially the presence of an &epsiv;4 allele, is more memorable than a numeric risk estimate for Alzheimer's disease. Participants recalled genotype information in a more simplified, binary form. Health professionals testing for complex disorders such as Alzheimer's disease must find an appropriate balance between communicating risk in an understandable format and addressing the probabilistic nature of the information.

KW - Alzheimer's disease

KW - APOE

KW - Genetic counseling

KW - Genetic susceptibility testing

KW - REVEAL

KW - Risk information recall

UR - http://www.scopus.com/inward/record.url?scp=33845765221&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=33845765221&partnerID=8YFLogxK

U2 - 10.1097/01.gim.0000250197.44245.a3

DO - 10.1097/01.gim.0000250197.44245.a3

M3 - Article

VL - 8

SP - 746

EP - 751

JO - Genetics in Medicine

JF - Genetics in Medicine

SN - 1098-3600

IS - 12

ER -